NEW YORK (GenomeWeb News) – Proteome Sciences and Millipore jointly announced today that they will collaborate on the development of multiplex immunoassays for Alzheimer's disease research.

Under terms of the deal, Millipore will develop the immunoassays on the Luminex platform to measure Proteome Sciences' Alzheimer's disease biomarkers. Billerica, Mass.-based Millipore will have exclusive rights to develop and sell Luminex bead-based panels for Alzheimer's research as well as other cognitive function disorders.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

Vox reports on inequities in genetic research and efforts to address them.

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Sponsored by

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.